While the core principles of dictionary coding for adverse events (AEs) are similar in both human and veterinary clinical trials, there are some key differences:

• Terminology: Veterinary medicine has its own specific terminology for diseases and adverse events, which is not always directly translatable to human terms. This necessitates the use of specialized veterinary dictionaries, such as the Veterinary Dictionary for Regulatory Activities (VeDDRA). VeDDRA provides standardized terminology for reporting suspected adverse events in animals, ensuring consistency and accuracy across different studies.

• Species Differences: Different animal species can experience very different AEs, and their responses to treatments can vary significantly. This requires a more nuanced approach to coding AEs in veterinary trials, as the dictionary needs to capture the full range of possible reactions for each species. For example, VeDDRA includes species-specific terms for AEs that are not relevant to humans, such as “wool slip” in sheep or “abortion” in pregnant animals.

• Lack of Standardization: While regulatory bodies like the European Medicines Agency (EMA) recommend the use of VeDDRA for veterinary clinical trials, it is not yet universally adopted. This can lead to inconsistencies in coding practices across different studies, making it difficult to compare data and draw meaningful conclusions. The ongoing development and adoption of standardized dictionaries like VeDDRA are crucial for improving the quality and reliability of AE data in veterinary trials.

• Limited Resources: Compared to human clinical trials, veterinary trials often have smaller budgets and fewer resources available. This can limit the availability of trained personnel and specialized software for coding AEs, potentially leading to inconsistencies and errors.

• Additional Considerations: Some additional considerations specific to veterinary trials include:
  1. Disease Models: Certain diseases in animals may not have a direct equivalent in humans, requiring the development of specific coding terms for these conditions and their associated AEs.
  2. Comorbidities: Animals in veterinary trials may have pre-existing conditions that can complicate the diagnosis and interpretation of AEs. This requires careful consideration when coding AEs to ensure accurate attribution to the study medication.
  3. Dosage and Administration: Differences in dosage and administration routes for veterinary drugs can affect the types and severity of AEs observed in studies. This needs to be factored in when coding AEs to ensure accurate comparisons across different trials.

In conclusion, while the overall objective of coding AEs in clinical trials remains the same for both humans and animals, the specific challenges and considerations in veterinary trials necessitate the use of specialized dictionaries and careful attention to ensure accurate and consistent reporting. The continued development and adoption of standardized practices are crucial for advancing the safety and efficacy of veterinary medicine.

Cloudbyz Unified Clinical Trial Management (CTMS) is a comprehensive, integrated solution to streamline clinical trial operations. Built on the Salesforce cloud platform, our CTMS provides real-time visibility and analytics across study planning, budgeting, start-up, study management, and close-out. Cloudbyz CTMS can help you achieve greater efficiency, compliance, and quality in your clinical operations with features like automated workflows, centralized data management, and seamless collaboration. Contact us today to learn how Cloudbyz CTMS can help your organization optimize its clinical trial management processes.

To know more about the Cloudbyz  Unified Clinical Trial Management Solution contact info@cloudbyz.com